Jeroen Elassaiss‐Schaap

Author

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

J Elassaiss-Schaap, J. Elassaiss-Schaap, Jeroen Elassaiss-Schaap, Jeroen Elassaiss‐Schaap

Publications

6.9K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of California, San Francisco University of California, Los Angeles The University of Sydney University of Pennsylvania

About

Jeroen Elassaiss‐Schaap is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	2.3K
2	Immunology	6	6	2.1K
3	Pathology	3	3	124
4	Engineering	1	1	15
5	Health Sciences	1	1	10

Jeroen Elassaiss‐Schaap

Publications

6.8K

Citations

H-Index

Page 1

	Year	Citations
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Omid Hamid, Caroline Robert, Adil Daud, New England Journal of Medicine	2013	3.4K
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Caroline Robert, Antoni Ribas, Jedd D. Wolchok, The Lancet OncologyMedicineIpilimumab-refractory Advanced MelanomaImmunologyMelanoma	2014	1.7K
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors Amita Patnaik, Soonmo Peter Kang, Drew Rasco, Clinical Cancer Research	2015	767
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab Richard W. Joseph, Jeroen Elassaiss‐Schaap, Richard Kefford, Clinical Cancer Research	2018	302
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors Malidi Ahamadi, Tomoko Freshwater, Marita Prohn, CPT Pharmacometrics & Systems Pharmacology Pembrolizumab ClearanceImmunologyMetronomic ChemotherapyImmunotherapyAdvanced Solid Tumors	2016	147
Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab Andreas Lindauer, CR Valiathan, Khamir Mehta, CPT Pharmacometrics & Systems Pharmacology ImmunologyPharmacotherapyImmunotherapyPhysiologically-based Pharmacokinetic ModelingHumanized Monoclonal Antibody	2016	117
Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial Jeroen Elassaiss‐Schaap, Stefaan Rossenu, Andreas Lindauer, CPT Pharmacometrics & Systems Pharmacology Keynote-001 TrialConfirm ”Pembrolizumab PksPharmacotherapySystem Pharmacology	2016	112
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma MS Chatterjee, Jeroen Elassaiss‐Schaap, Andreas Lindauer, CPT Pharmacometrics & Systems Pharmacology ImmunologyPathologyImmunotherapyPharmacodynamic ModelingPopulation Pharmacokinetic/pharmacodynamic Modeling	2016	79
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations Mohammed A. A. Saleh, Chi Fong Loo, Jeroen Elassaiss‐Schaap, Journal of Pharmacokinetics and Pharmacodynamics	2021	37
Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475. Richard W. Joseph, Jeroen Elassaiss‐Schaap, Jedd D. Wolchok, Journal of Clinical Oncology Cancer ManagementPrognosisImmunologyPathologyOverall Survival	2014	35

Page 1